Small molecule inhibiting microglial nitric oxide release could become a potential treatment for neuroinflammation

PLoS One. 2023 Feb 6;18(2):e0278325. doi: 10.1371/journal.pone.0278325. eCollection 2023.

Abstract

Microglia are the immune effector cells of the central nervous system (CNS) and react to pathologic events with a complex process including the release of nitric oxide (NO). NO is a free radical, which is toxic for all cells at high concentrations. To target an exaggerated NO release, we tested a library of 16 544 chemical compounds for their effect on lipopolysaccharide (LPS)-induced NO release in cell line and primary neonatal microglia. We identified a compound (C1) which significantly reduced NO release in a dose-dependent manner, with a low IC50 (252 nM) and no toxic side effects in vitro or in vivo. Target finding strategies such as in silico modelling and mass spectroscopy hint towards a direct interaction between C1 and the nitric oxide synthase making C1 a great candidate for specific intra-cellular interaction with the NO producing machinery.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell Line
  • Humans
  • Infant, Newborn
  • Lipopolysaccharides / metabolism
  • Lipopolysaccharides / pharmacology
  • Microglia* / metabolism
  • Neuroinflammatory Diseases
  • Nitric Oxide Synthase Type II / metabolism
  • Nitric Oxide* / metabolism

Substances

  • Nitric Oxide
  • Nitric Oxide Synthase Type II
  • Lipopolysaccharides

Grants and funding

The German Research Foundation (grant number TR 43 to SAW and HK) funded this study. In addition, SAW has received funding from a support association for eye diseases (e.V.) “Förderverein für Augenkrankheiten” to conduct the SAR. The authors declare no competing interests. The funders had no role in study design, data collection and alalysis, decision to publish, or preparation of the manuscript.